Exocrine Pancreatic Insufficiency Treatment Market – By Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy), Drug Type (Creon, Zenpep, Pancreaze, Ultresa, Viokace), Indication, Distribution Channel – Global Forecast (2024 – 2032)

Exocrine Pancreatic Insufficiency Treatment Market Size

Exocrine pancreatic insufficiency treatment market size was valued at around USD 3.2 billion in 2023 and is estimated to grow at 6.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency (EPI) is a condition characterized by the inadequate production or secretion of digestive enzymes by the pancreas.
 

The pancreas normally produces enzymes such as lipase, protease, and amylase are essential for the digestion of fats, proteins, and carbohydrates in the small intestine. Treatment primarily revolves around enzyme replacement therapy (ERT), where deficient digestive enzymes are supplemented to aid digestion and absorption. The goal of ERT is to enhance nutrient uptake, alleviate symptoms, and prevent malnutrition-related complications. Through tailored enzyme supplementation, ERT aims to restore digestive function and improve the quality of life for individuals with EPI.
 

The increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis serves as a substantial impetus for market growth. For instance, according to the National Institutes of Health (NIH) in 2023, reported a prevalence of chronic pancreatitis ranging from 13.5 to 163 cases per 100,000 individuals. Additionally, the incidence of CP was found to range from 5 to 31.7 new cases per 100,000 person-years. This underscores the growing need for effective treatments and management strategies for conditions such exocrine pancreatic insufficiency treatment (EPI), often arises as a complication of chronic pancreatitis and cystic fibrosis. Furthermore, growing aging population, advancements in diagnosis, and technological innovations are the promoting factors fostering the growth of the market.
 

Exocrine Pancreatic Insufficiency Treatment Market Trends

Technological advancements surround the exocrine pancreatic insufficiency treatment (EPI) market. These advancements have revolutionized various aspects of EPI management, ranging from early detection to personalized treatment approaches. With a growing understanding of the complexities underlying pancreatic dysfunction and the diverse needs of EPI patients, researchers and healthcare innovators have been leveraging cutting-edge technologies to improve diagnostic accuracy, enhance therapeutic efficacy, and empower individuals to better manage their condition.
 

• Ongoing research and development have led to the creation of more effective and stable pancreatic enzyme formulations for pancreatic enzyme replacement therapy (PERT). These formulations aim to optimize enzyme activity, enhance stability in the gastrointestinal tract, and improve absorption, thereby increasing the efficacy of digestion and symptom control in patients with EPI.
   
• Advanced drug delivery systems such as enteric-coated tablets, gastro-resistant capsules, and oral enzyme formulations with bile acid sequestrants help to optimize the delivery of pancreatic enzymes to the intestine while protecting them from premature degradation in the stomach. These innovative delivery systems improve the absorption and efficacy of enzyme supplements and enhance patient compliance with treatment regimens.
   
• Innovations in nutritional support have been beneficial for EPI patients, often struggle with malabsorption and nutrient deficiencies. This includes the development of specialized enteral nutrition formulas that are better tolerated and absorbed by individuals with EPI, as well as technologies for monitoring and optimizing nutritional status. Thus, escalating the growth of the market.
   

Exocrine Pancreatic Insufficiency Treatment Market Analysis

Based on treatment, the market is bifurcated nutritional management and pancreatic enzyme replacement therapy (PERT). The pancreatic enzyme replacement therapy (PERT) segment accounted for USD 2.4 billion in 2023.
 

• PERT supplements provide exogenous pancreatic enzymes such as lipase, protease, and amylase are essential for breaking down fats, proteins, and carbohydrates in the small intestine. By restoring enzymatic activity, PERT helps compensate for the deficient pancreatic enzyme secretion seen in EPI, facilitating proper digestion and nutrient absorption.
   
• It can alleviate symptoms associated with EPI including abdominal pain, bloating, diarrhea, and weight loss. By improving digestion and reducing malabsorption, PERT helps alleviate gastrointestinal symptoms, improving patients' overall quality of life.
   
• Additionally, PERT is available in various formulations and strengths, allowing for personalized dosing based on individual patient needs and dietary fat content. Thus, driving the growth of the market.
   

Based on drug types, the exocrine pancreatic insufficiency treatment market is bifurcated into creon, zenpep, pancreaze, ultresa, viokace and other drug types. The creon segment is estimated to account for USD 2 billion by 2032.
 

• Creon contains a combination of pancreatic enzymes including lipase, protease, and amylase, mimic the natural enzymes produced by the pancreas. This formulation ensures effective digestion of fats, proteins, and carbohydrates, thereby addressing the underlying cause of EPI and improving nutrient absorption.
   
• Further, it is available in different strengths, allowing healthcare providers to tailor the dosage to the individual needs of each patient. This customization enables optimal control of symptoms and ensures adequate enzyme supplementation based on factors such as the severity of EPI and dietary fat intake.
   

Based on indication, the exocrine pancreatic insufficiency treatment market is bifurcated into abdominal pain, constipation, diarrhoea, fatty stools, weight loss and other indications. The abdominal pain segment accounted for USD 648.5 million in 2023.
 

• Treating the underlying cause of EPI such as chronic pancreatitis or cystic fibrosis, can help alleviate abdominal pain. This may involve lifestyle modifications, medication management, or surgical interventions as appropriate.
   
• Further, in cases chronic pancreatitis contributes to EPI and abdominal pain, anti-inflammatory drugs, which is estimated to reach USD 233.6 billion by 2032, can be prescribed to reduce inflammation and alleviate pain.
   
• Additionally, non-pharmacological approaches such as heat therapy, relaxation techniques, and physical therapy may help manage abdominal pain associated with EPI. Additionally, pharmacological interventions such as pain relievers or muscle relaxants may be prescribed to alleviate discomfort.
   

Based on distribution channel, the exocrine pancreatic insufficiency treatment market is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies. The hospital pharmacies segment is estimated to account for USD 2.8 billion by end of 2032.
 

• Hospital pharmacies often have access to a wide range of specialized formulations of pancreatic enzyme supplements including enteric-coated tablets, gastro-resistant capsules, and microencapsulated formulations. These formulations are tailored to optimize enzyme activity, enhance stability, and improve absorption in patients with EPI.
   
• Hospital pharmacists are highly trained professionals with expertise in medication management including the dispensing, compounding, and dosing of pancreatic enzyme replacement therapy (PERT). They ensure accurate prescription filling, provide dosage adjustments based on individual patient needs, and offer counseling on medication use and potential side effects.
   
• Further, hospital pharmacists work collaboratively with physicians, dietitians, and other healthcare providers to develop individualized treatment plans for patients with EPI. They participate in multidisciplinary care teams, providing medication expertise and contributing to the overall management of the patient's condition.
   

The North America exocrine pancreatic insufficiency treatment market is accounted for USD 1.4 billion in 2023.
 

• The U.S. boasts a robust healthcare infrastructure with world-class hospitals, medical centers, and research institutions equipped with state-of-the-art technology and resources for diagnosing, treating, and researching EPI.
   
• The country is home to numerous healthcare professionals specializing in pancreatic disorders including gastroenterologists, pancreatologists, endocrinologists, and dietitians. These specialists have extensive experience in managing EPI and can provide comprehensive and tailored care to patients.
   

The exocrine pancreatic insufficiency treatment market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany is home to specialized pancreatic centers and clinics that focus on the diagnosis and treatment of pancreatic disorders, including EPI. These centers often have multidisciplinary teams of specialists that collaborate to provide comprehensive care to patients, further fueling market growth.
   

Japan exocrine pancreatic insufficiency treatment market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan is at the forefront of medical technology with access to innovative diagnostic techniques and imaging modalities for assessing pancreatic function and detecting EPI-related complications. These advanced tools aid in accurate diagnosis and monitoring of the condition.
   

The exocrine pancreatic insufficiency treatment market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia collaborates with international medical institutions and experts, allows for the exchange of knowledge, research findings, and best practices in managing pancreatic disorders such as EPI. This collaboration contributes to the continuous improvement of healthcare services in the country.
   
• The government of Saudi Arabia has implemented public health initiatives aimed at improving the overall health and well-being of its population, including initiatives focused on chronic disease management and preventive care.
   

Exocrine Pancreatic Insufficiency Treatment Market Share

The exocrine pancreatic insufficiency treatment industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Exocrine Pancreatic Insufficiency Treatment Market Companies

Some of the eminent market participants operating in the exocrine pancreatic insufficiency treatment industry include:

• Abbott Laboratories                      
• AbbVie Inc.                        
• Allergan plc                       
• Alexion Pharmaceuticals, Inc.                             
• Anthera Pharmaceuticals Inc.                             
• Amgen Inc.                        
• AstraZeneca Plc                            
• BioMarin Pharmaceutical Inc.                             
• Cilian AG                           
• Digestive Care, Inc.                      
• Eli Lilly and Company                              
• Johnson & Johnson                       
• Nordmark Arzneimittel GmbH & Co. KG              
• Sanofi           
• Takeda Pharmaceutical Company Limited
   

Exocrine Pancreatic Insufficiency Treatment Industry News:

• In October 2023, Amgen acquired Horizon Therapeutics plc, a developer of innovative medicines. This strategic move positioned Amgen to deliver enhanced value to patients and healthcare providers while strengthening its competitive position in the medications market.
   

The exocrine pancreatic insufficiency treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Nutritional management                                   
• Pancreatic enzyme replacement therapy (PERT) 

Market, By Drug Type

• Creon
• Zenpep
• Pancreaze
• Ultresa
• Viokace
• Other drug types

Market, By Indication

• Abdominal pain       
• Constipation  
• Diarrhea       
• Fatty stools   
• Weight loss
• Other indications

Market, By Distribution Channel         

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies                       

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa